{"id":"sitagliptin-novartis-usa","safety":{"commonSideEffects":[{"rate":"7-10","effect":"Nasopharyngitis"},{"rate":"5-7","effect":"Headache"},{"rate":"5-7","effect":"Upper respiratory tract infection"},{"rate":"1-5","effect":"Hypoglycemia (when combined with other agents)"},{"rate":null,"effect":"Pancreatitis"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Sitagliptin is a DPP-4 inhibitor that prevents the degradation of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP). By extending the half-life of these incretin hormones, the drug enhances glucose-dependent insulin secretion and suppresses glucagon release, thereby lowering blood glucose levels in patients with type 2 diabetes. This mechanism is glucose-dependent, meaning it primarily works when blood glucose is elevated, reducing hypoglycemia risk.","oneSentence":"Sitagliptin inhibits dipeptidyl peptidase-4 (DPP-4), prolonging the activity of incretin hormones to increase insulin secretion and decrease glucagon in response to meals.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:08:27.844Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT07083232","phase":"PHASE4","title":"The Effect of Sitagliptin, Pioglitazone and Dapagliflozine on Myocardial Infarction in Diabetic Rats","status":"COMPLETED","sponsor":"Al-Azhar University","startDate":"2024-10-30","conditions":"Diabetic, Myocardial Infarction","enrollment":50}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Sitagliptin (Novartis, USA)","genericName":"Sitagliptin (Novartis, USA)","companyName":"Al-Azhar University","companyId":"al-azhar-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Sitagliptin inhibits dipeptidyl peptidase-4 (DPP-4), prolonging the activity of incretin hormones to increase insulin secretion and decrease glucagon in response to meals. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}